Status:
COMPLETED
Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss
Lead Sponsor:
RESnTEC, Institute of Research
Conditions:
Pregnancy Loss
Eligibility:
FEMALE
18-44 years
Phase:
NA
Brief Summary
Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of su...
Eligibility Criteria
Inclusion
- Pregnant females between 18 and 44 years of age
- Gestational age above 8 weeks
- A history of ≥3 consecutive first trimester pregnancy losses
Exclusion
- Patients with systemic lupus erythematosus
- Positive IgG and IgM anticardiolipin antibodies
- Positive for thrombophilia screening
- Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
- Sensitive to acetylsalicylic acid, heparin, or warfarin
- Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT06484634
Start Date
December 1 2023
End Date
May 31 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DG Khan Hospital
Dera Ghazi Khan, Punjab Province, Pakistan, 32200